Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Melior Discovery said that the USTPO has awarded a Notice of Allowance (NOA)for a broad patent application covering the company’s use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity.
Subscribe to our email newsletter
The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.
MLR-1023 is a repositioned small molecule drug candidate that Melior Discovery is developing for the treatment of type II diabetes. Previously, the compound was advanced through Phase II clinical trials for the treatment of gastric ulcers, but was discontinued due to lack of efficacy in that indication.
Using its theraTRACE platform, Melior Discovery has uncovered a potential utility of MLR-1023 for the treatment of diabetes. MLR-1023 is expected to be a first-in-class, once-per-day, orally administered drug that reduces blood glucose levels, with a side effect profile that is favorable compared to available therapies.
MLR-1023 exerts its glycemic control activity via a novel mechanism, the activation of enzyme lyn kinase. Melior Discovery received approval from the US FDA for an IND in 2009.
Andrew Reaume, president and CEO of Melior Discovery, said: “This recent patent notification offers the potential for robust patent protection for MLR-1023, Melior’s lead drug candidate for diabetes, and represents a significant milestone for the Company.”